This document relates generally to implantable medical devices and more particularly to a method and system for monitoring placement and/or adjustment of an implantable devices for treating urinary incontinence.
An example of an implantable device for treating urinary incontinence includes an adjustable membrane element, such as a balloon, connected to a rear port with a conduit. The implantable device can be implanted in a patient with the adjustable membrane element placed adjacent to the patient's urethra and the rear port placed underneath the patient's skin by a minimally invasive surgery. The adjustable membrane element can be adjusted during and after the surgery by injecting fluid into the rear port or extracting fluid from the rear port percutaneously using a needle. In an exemplary treatment, two of such implantable devices are placed in the patient such that the two adjustable membrane elements provide pressure and support at the patient's bladder neck to protect against accidental leaking of urine during sneeze, cough, or physical activity. The efficacy of this treatment depends on proper placement in the patient and adjustment of the adjustable membrane element after the placement.
One or more sensors are incorporated onto one or more of an implantable device and a surgical tool used for placement and/or adjustment of the implantable device. The implantable device includes an adjustable membrane element for controllable coaptation of a body lumen, such as coaptation of a urethra as treatment for urinary incontinence. In various embodiments, the one or more sensors can be configured to detect information indicative of at least one of a shape of the adjustable membrane element, a position of the adjustable membrane element relative to the body lumen, or a shape of the body lumen.
In various embodiments, an implantable device for controllable coaptation of a body lumen can include an adjustable membrane element and an elongate conduit. The adjustable membrane element can include a continuous wall having an inner surface defining a chamber. The elongate conduit can include a peripheral surface connected to and sealed to the adjustable membrane element, a rear end, a front end, and a lumen extending longitudinally in the elongate conduit from a first opening at the rear end to a second opening in fluid communication with the chamber of the implantable device for adjustably expanding or contracting the adjustable membrane element by applied flowable material introduced through the first opening. One or more sensors can be incorporated into the implantable device and/or a sensor probe for monitoring positioning of the implantable device, adjustment of the implantable device, and/or state of coaptation of the body lumen. In one embodiment, one or more sensors are incorporated onto at least one of the adjustable membrane element or the elongate conduit of the implantable device. In another embodiment, a sensor probe includes a front end into which a sensor incorporated. In one embodiment, the lumen of the elongate conduit is configured to accommodate a portion of the sensor probe including its front end. In another embodiment, the implantable device includes another lumen extending longitudinally in the elongate conduit and having an inlet configured to receive a portion of the sensor probe and a closed end to stop the sensor probe or an outlet configured to allow a portion of the sensor probe including its front end to exit. In various embodiments, the one or more sensors can include one or more optical sensors, such as cameras or borescopes, and/or one or more ultrasonic transducers for producing an ultrasonic image.
This summary is an overview of some of the teachings of the present application and not intended to be an exclusive or exhaustive treatment of the present subject matter. Further details about the present subject matter are found in the detailed description and appended claims. The scope of the present invention is defined by the appended claims and their legal equivalents.
The following detailed description of the present subject matter refers to subject matter in the accompanying drawings which show, by way of illustration, specific aspects and embodiments in which the present subject matter may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the present subject matter. References to “an”, “one”, or “various” embodiments in this disclosure are not necessarily to the same embodiment, and such references contemplate more than one embodiment. The following detailed description is demonstrative and not to be taken in a limiting sense. The scope of the present subject matter is defined by the appended claims, along with the full scope of legal equivalents to which such claims are entitled.
This document discusses, among other things, a system and method for monitoring placement and/or adjustment of an implantable device for treating urinary incontinence. The implantable device can include, for example, an adjustable membrane element connected to a rear port with a conduit that has a lumen providing for fluid communication between a chamber of the adjustable membrane element and an interior cavity of the rear port. Various structural elements of the implantable device (e.g., the implantable device 110 shown in
In an example, the implantable device includes an adjustable balloon connected to a port with a conduit. The balloon is placed adjacent the urethra to exert non-circumferential compression upon the urethral wall. The effectiveness of the therapy depends on proper positioning of the balloon in a patient's body, such as in retropubic space (resulting from a radical prostatectomy) near the urethra-vesical anastomosis above the urogenital diaphragm in close proximity to the urethral walls. When two balloons (e.g., of two implantable devices) are used, their preferred positioning is usually symmetrical and lateral with respect to the urethra. Fluoroscopy or transrectal ultrasonography can be used to visually monitor the positioning of the balloon(s) during the implantation of the implantable device(s). Fluoroscopy has become a standard technique, but exposes the patient to radiation and provides a two-dimensional view that presents viewing difficulties under some circumstances. For examples, when the patient is on operation table, the fluoroscopic image does not show the location of the balloons on the anterior-posterior plane, and therefore does not show whether the balloons are properly positioned to exert compression upon the urethral wall. Transrectal ultrasonography (TRUS) can provide for better viewing (e.g., the location of the balloons on the anterior-posterior plane) but requires the surgeon to be familiar with this imaging technique. During an implantable process, implantable device(s) are initially placed in the patient with the balloon(s) positioned in the target space(s). The balloon(s) can be left slightly inflated to allow for encapsulation (by the patient's tissue) without migration from the target space(s). After the encapsulation, the patient will go through one or more adjustment procedures during which the balloon(s) are adjusted to obtain and maintain urinary continence without causing undesirable obstruction.
The present subject matter uses one or more sensors incorporated onto the implantable device and/or a surgical tool for implanting the implantable device to monitor the placement and/or adjustment of the implantable device(s). This monitoring technique avoids use of fluoroscopy or transrectal ultrasonography and their disadvantages such as exposure to x-ray or rectal insertion of ultrasonic probe. In one embodiment, the one or more sensors include one or more ultrasonic transducers on the implantable device and/or the surgical tool allow for ultrasonic imaging to be used to monitor the placement and adjustment of the balloon(s) during device implantation. The ultrasonic sensor(s) on the implantable device can further allow for post-operative adjustment of the balloon(s).
In various embodiments, the present subject matter provides sensing means for monitoring, for example, location of each balloon and amount of inflation (expansion) of each balloon. In various embodiments, the sensing means can also be used for monitoring various states of the urethra that can indicate an amount of compression resulting from a degree of expansion of the balloon, such as excessive compression resulting from over-inflation of the balloon, adequate compression (target of the treatment), and insufficient compression resulting from under-inflation of the balloon. The target of the treatment is to provide the patient with continence without undesirable obstruction, and this requires the right amount of coaptation of the urethra resulting from placing the balloon(s) in the right position(s) and giving each balloon the right amount of inflation. The present subject matter allows for determination of the right position and right amount of inflation for each balloon.
According to the present subject matter as shown by
As further shown in
An important feature of the implantable device 110 having the first lumen 215 includes a first opening port 215A located in cavity 216A of the rear port 116 between an elastic septum 218 and the conduit 114 and is connected to the first lumen 215, so that a flowable material can be infused therethrough, and a second port 215B serves to direct the working fluid to the adjustable membrane element 112. During adjustment of the volume of the membrane fluid provided from a hollow needle 121 of syringe 120, is infused through the septum 218 and continues through the conduit 114 connected to the adjustable membrane element 112. The rear port 116 preferably has a diameter greater than conduit 114 to accommodate the cavity 216A and the septum 218, which is retained securely by a clamp ring 119.
The entire implantable device 110 including the adjustable membrane element 112 is formed of a biocompatible material such as silicone or polyurethane elastomer, and the conduit 114 and the rear port 116 may be formed as a unitary construction. Optionally, the adjustable membrane element 112, the rear port 116, and the conduit 114 can be molded as one piece. As shown in
The implantable device and assembly according to the present subject matter can include three main members. The first member provided is an elongate guide in the form of a stiff solid elongate guide probe 424 (see
During the implantation of the implantable device 110, a physician can first make a small incision in the skin 430 of the patient near a body lumen 432 that needs to be restricted, and then by visualization means such as fluoroscopy or ultrasonic imaging, the solid guide probe 424 is directed to the desired location, depending upon the anatomy of the patient. Thereafter, the opening 117A of the second lumen 117 of the conduit 114 with the adjustable membrane element 112 in its initial deflated or contracted condition, is slid over the rear end 424A of the guide probe 424. The guide probe 424 slides through the second lumen 217 of the conduit 114 and exits at the rearward opening 117B. As illustrated in
If desired, a mark 533 can be provided on the guide probe 424 which when aligned with a feature on the implantable device 110 such as the rear port 116 can assure that the implantable device 110 is appropriately placed at the correct depth in the patient's body tissue 430. It may be necessary to provide the conduit 114 in multiple lengths to facilitate placement of the septum 218 near the patient's skin. Alternatively, an effective length of the conduit 114 can be made adjustable by it having a helical shape similar to that of a coiled spring.
After the implantable device 110 has been advanced over guide probe 424 so that the contracted adjustable membrane element 112 is in the desired position adjacent to the body lumen 432, the body lumen 432 may be restricted to a desired degree by piercing septum 218 with the needle 121 of syringe 120 and injecting a flowable material through the first lumen 215 into the adjustable membrane element 112. The physician can determine the desired degree of restriction of body lumen 432 by means such as infusing fluid through the body lumen past the restriction and measuring the back pressure.
As illustrated by
An alternative method of delivery of the implantable device 110 can be to first withdraw the guide probe 24 from the body tissue and then inflate the adjustable membrane element 112. A further alternative would be to first place the implantable device 110 over the solid guide probe 424 outside the body and then insert them both into the body tissue as a unit. To facilitate this latter procedure, it may be desirable that there be some friction between the solid guide probe 424 and the second lumen 217 in the conduit 114.
After the implantable device 110 has been properly positioned with the adjustable membrane element 112 located near the body lumen 432 and the septum 218 in the rear port 116 located near the skin 430, the device is injected with a flowable material from the syringe 120. The expandable member can be inflated to a certain extent and then deflated to an extent suitable for encapsulation of the expandable member by body tissue. The guide probe 24 is then withdrawn from the device, leaving the slightly expanded membrane element in the body tissue. Then the skin incision 431 is closed over the port 116 by means such as a suture 834 as shown in
The present subject matter provides the implantable device 110 with adjustability of the membrane expansion post-operatively. This adjustability is effected because the septum 218 is located remote from the adjustable membrane element 112 but near and under the patient's skin. The port and septum is located by, for instance, manual palpation of the skin region and the needle of the syringe is inserted through the skin and septum to add or remove material from the expandable member, thus increasing or decreasing the restriction of the body lumen.
To assure proper sealing of the septum 218, it is placed in compression within a cavity 216A by providing a tight metal ring 119 that surrounds the rear port 116 and is smaller in diameter than the port. When the needle 121 of the syringe 120 is withdrawn from the septum 218 after expansion or adjustment of the adjustable membrane element 112, there is positive sealing around the perimeter of the septum 218.
After the desired location within the body tissue has been reached, a suitable flowable material is introduced into the implantable device 110 from a source such as the syringe 120 having hollow needle 121 inserted through septum 218 to at least partially expand the adjustable membrane element 112, as shown by
The implantable device kit 940 further includes a rear port 916, where the rear port 916 is coupled to the rear end 962 of the conduit 914. In one embodiment, the rear port 916 is coupled to the rear end 962 of the elongate body 914 using chemical adhesives, or alternatively, using sonic welding techniques as are known in the art. In an additional embodiment, the rear port 916 and rear end 962 are formed together in a polymer molding process, such as liquid injection molding, as are known in the art.
The rear port 916 includes a cavity 916A, where the cavity 916A is in fluid communication with the first opening 915A of the conduit 914. In one embodiment, the rear port 916 also includes an elastic septum 918 through which the cavity 916A is accessed, where the elastic septum 918 is a sealable after repeated pierces, for example, with a needle. In one embodiment, the elastic septum 918 is retained in the rear port 916 by a clamp ring 919 located around the rear port 916. In one embodiment, the clamp ring 919 is made of a biocompatible material, such as, for example, titanium. In one embodiment, the elastic septum 918 is made of a biocompatible material, such as, for example, silicone or polyurethane. The rear port 916 has an outer diameter defined by an outer surface 954 of the rear port 916. In one embodiment, the rear port 916 has an outer diameter of 1 to 15 millimeters, with 4.5 millimeters being a specific example.
In one embodiment, the outer surface of the rear port 916 and the adjustable membrane element 912 are of a size (e.g., a diameter) that is smaller than an inner size (e.g., a diameter) of the channel 944 to allow the implantable device 910 to be moved longitudinally through the channel 944 of the sheath 946. In an alternative embodiment, the rear port 916 is constructed of at least one material flexible enough to allow the size of the rear port 916 in its relaxed state to be compressed to a size sufficiently small so that the implantable device 910 can be moved longitudinally through the channel 944 of the sheath 946. In various embodiments, the conduit 914 has a stiffness sufficient to allow force applied at the rear end of its tubular elongate body to move the implantable device 910 at least partially through the channel 944 of the sheath 946. In one embodiment, the stiffness of the conduit 914 is determined based on the type of material used in constructing its tubular elongate body. Alternatively, support elements can be added to the tubular elongate body. For example, a metal coil can be placed longitudinally within the tubular elongate body to increase the stiffness of the tubular elongate body.
Once the implantable device 910 is positioned within a body, the adjustable membrane element 912 is inflated by releasably connecting a flowable material source to the rear port 916. In one embodiment, the flowable material source includes a syringe with a non-coring needle, where the needle is inserted through the elastic septum 918. A measured supply of fluid volume can be introduced into the implantable device 910, and the adjustable membrane element 912 expands or contracts due to a volume of flowable material introduced into the cavity 916A of the rear port 916 from the flowable material source. The adjustable membrane element 912 is then used to at least partially and adjustably restrict the body lumen. Fluids suitable for infusing into the prosthesis include, but are not limited to, sterile saline solutions, polymer gels such as silicone gels or hydrogels of polyvinylpyrrolidone, polyethylene glycol, or carboxy methyl cellulose for example, high viscosity liquids such as hyaluronic acid, dextran, polyacrylic acid, polyvinyl alcohol, or a radio-opaque fluid for example. Once the adjustable membrane element 912 has been inflated, the needle is withdrawn from the septum of the rear port 916. In an additional embodiment, a detectable marker 970 is imbedded in the continuous wall of the adjustable membrane element 912. The detectable marker 970 allows the adjustable membrane element 912 to be located within the tissues of a patient using any number of visualization techniques which employ electromagnetic energy as a means of locating objects within the body. In one embodiment, the detectable marker 970 is constructed of tantalum and the visualization techniques used to visualize the adjustable membrane element 912 are x-ray or fluoroscopy as are known in the art.
In an additional embodiment, a detectable marker is imbedded in the implantable device 910. For example, the detectable marker 970 is located at a front end (also referred to as a distal end) 960 (e.g., the tip) of the conduit 914. Alternatively, the detectable marker can be located in the continuous wall of the adjustable membrane element 912. The detectable marker 970 allows the front end 960, or the adjustable membrane element 912, to be located within the tissues of a patient using any number of visualization techniques which employ electromagnetic energy as a means of locating objects within the body. In one embodiment, the detectable marker 970 is constructed of tantalum and the visualization techniques used to visualize the front end 960, or the adjustable membrane element 912, are x-ray or fluoroscopy as are known in the art. In an additional embodiment, the sheath could also have a detectable marker, where the marker could be incorporated into, or on, the wall of the sheath. Alternatively, the entire sheath could be constructed to be radio-opaque.
The conduit 1014 includes a first lumen 1015 and a second lumen 1017. In one embodiment, the first lumen 1015 extends longitudinally in the conduit 1014 from a first opening 1015A to one or more second openings 1015B (e.g., two openings as shown in
The second lumen 1017 extends longitudinally along the conduit 1014 from an inlet 1017B to a closed end 1017A at the front end 1060. In one embodiment, the second lumen 1017 and the inlet 1017B are each of sufficient diameter to receive a push rod that can be used to advance the implantable device 1010 in the tissue.
The implantable device 1010 further includes a rear port 1016, which is coupled to the rear end of the conduit 1014. In one embodiment, the rear port 1016 is similar to the rear port 916 and includes a cavity 1016A and an elastic septum 1018. The cavity 1016A coupled to and in fluid communication with the first lumen 1015 at the first opening 1015A. The elastic septum 1018 allows for excess to the cavity 1016A using a needle, for introducing and/or withdrawing fluid to expand and/or extract the adjustable membrane element 1012.
The sensor probe 1324 has an elongate body 1326 having a rear end 1327 a front end 1325, and one or more sensors 1328 incorporated onto the elongate body 1326. In various embodiments, the sensor probe 1324 can be constructed by incorporating the sensor(s) 1328 into any surgical tool that is used during the implantation and/or adjustment of the implantable device 1310 and has an elongate body. Examples of such a surgical tool include a push rod (e.g., push rod 1450) and a guide probe (or guide rod or guide wire, e.g., guide probe 424). In one embodiment, as illustrated in
In various embodiments, the sensor(s) 1328 can be rotated by rotating the elongate body 1326, such as by rotating the rear end 1327. The elongate body 1326 can include a sensor connection circuit 1330, such as at the rear end 1327. Conductors 1329 extend within the elongate body 1326 to provide connections between sensor(s) 1328 and sensor connection circuit 1330. In one embodiment, sensor connection circuit 1330 includes a connector for connection to an external system that processes signals sensed by sensor(s) 1328. In another embodiment, sensor connection circuit 1330 includes a telemetry circuit and a battery such that it can communicate with the external system wirelessly. The telemetry circuit can perform the wireless communication using, for example, electromagnetic, magnetic, acoustic, or optical telemetry.
In various embodiments, sensor(s) 1328 can include one or more ultrasonic transducers each to convert an electrical input signal to ultrasound, transmit the ultrasound, receive a reflected ultrasound (echo of the transmitted ultrasound), and convert the received reflected ultrasound to an electrical image signal. The external system can receive the electrical image signal and produce an ultrasonic image based on the electrical image signal. The one or more ultrasonic transducers can each include a piezoelectric transducer or a capacitive transducer, and each have an ultrasonic beam direction and an ultrasonic beam angle.
In various embodiments, sensor(s) 1328 can include one or more optical sensors. The one or more optical sensors can each include a charge-coupled device (CCD) image sensor or an active pixel sensor (APS, also known as complementary metal-oxide-semiconductor (CMOS) image sensor) to convert captured image to an electrical image signal. The external system can receive the electrical image signal and produce a visual image based on the electrical image signal.
In various embodiments, the lumen of the implantable device 1310 that is in fluid communication with the chamber is also configured to receive the sensor probe 1324, which is used as a push rod (e.g., as illustrated in
In various other embodiments, a first lumen of the implantable device 1310 is in fluid communication with the chamber for adjusting the volume of the chamber, and the implantable device 1310 includes a second lumen extending longitudinally within at least a portion of the conduit 1314 and configured to receive the sensor probe 1324 (e.g., as illustrated in
In one embodiment, the second lumen includes a closed end near the front end 1313 of the conduit 1314. This closed end has sufficient strength and hardness to receive the front end 1325 of the sensor probe 1324 and transfers force applied at the rear end 1327 of the sensor probe 1324 to the implantable device 1310.
In another embodiment, the sensor probe 1324 includes a sharp tip suitable for penetrating tissue, as in the example illustrated in
In various embodiments, sensor(s) 1828 can include one or more ultrasonic transducers each to convert an electrical input signal to ultrasound, transmit the ultrasound, receive a reflected ultrasound (echo of the transmitted ultrasound), and convert the received reflected ultrasound to an electrical image signal. An external system can receive the electrical image signal and produce an ultrasonic image based on the electrical image signal. The one or more ultrasonic transducers can each include a piezoelectric transducer or a capacitive transducer, and each have an ultrasonic beam direction and an ultrasonic beam angle. A plurality of ultrasonic transducers can be arranged on the implantable device 1810 to provide a specified overall ultrasonic beam angle (e.g., 90, 180, 270, or 360 degrees).
In various embodiments, sensor(s) 1828 can include one or more optical sensors. The one or more optical sensors can each include a CCD image sensor or an APS to convert captured image to an electrical image signal. The external system can receive the electrical image signal and produce a visual image based on the electrical image signal.
In various embodiments, sensor(s) 1828 can include one or more of any type that can sense signals useful in assisting the placement and adjustment of the implantable device 1810, such as pressure sensors and strain gauges.
The sensor connection circuit 1840 can be within the rear port 1316 and provide for access to the one or more sensors 1828 via the rear port 1316. In one embodiment, the implantable deice 1810 can communicate with the external system using a wired connection. The sensor connection circuit 1840 includes a connector. The external system includes a percutaneous connector to pierce the elastic septum of the rear port 1316 and mate the connector in the rear port 1316. In another embodiment, the implantable deice 1810 can communicate with the external system wirelessly. The sensor connection circuit 1840 includes a telemetry circuit and a battery or inductive power receiver. The telemetry circuit can transmit power to the implantable device 1810 and receive the sensed signals from the implantable device 1810.
As shown in
In the illustrated embodiment, the sensor 2328 is an optical sensor for visually observing the flattening of the adjustable membrane element 2312 against the urethra as a proxy for actual visualization of coaptation within the urethra. In another embodiment, the sensor 2328 is an ultrasonic sensor. In addition to directly observing the coaptation of the urethra, if the ultrasonic sensor transmits an ultrasound having sufficient depth of penetration within the tissue, it may also allow for visualization of the adjustable membrane element 2312 in relation to anatomic structures such as the bladder neck and the rectum. Such visualization can be used to aid placement of the adjustable membrane element 2312 during the implantation of the implantable device 2310. In various embodiments, the sensor 2328 can include any type of sensor that allows for detection of the flattening of the adjustable membrane element 2312 and/or visualization of the adjustable membrane element 2312 in the tissue in relation to various anatomic structures.
In the illustrated embodiment, the sensor 2328 (i.e., the optical sensor) includes an optical sensing element 2361 for observing the flattening of the adjustable membrane element 2312 with a CCD or CMOS chip 2362 that obtains a radial view with the aid of a mirror 2363. The chip 2362 is powered, and data acquired by the sensor 2328 are returned, via filament 2364. The filament 2364 can also be used to power a light source such as an LED to aid in visualization (which is unnecessary if the chip 2362 is an infrared CCD or CMOS chip). The sensor probe 2324 can be rotated about its longitudinal axis within the lumen 2315 to scan circumferentially to find the point of maximum coaptation where the adjustable membrane element 2312 is flattened. Rotating the sensor probe 2324 can also aid in passing it through curves in the conduit 2314, especial when the rear port 2316 is routed into the scrotum or labia. At least for this reason, the sensor probe 2324 is provided with a certain amount of flexibility. In one embodiment, the sensor probe 2324 with the optical sensor 2328 is equipped with a wide-angle lens to allow for viewing the entire internal surface of the adjustable membrane element 2312 such that circumferential scanning would not be necessary.
In another embodiment, the sensor probe 2324 can include a borescope for optical visualization with a fiber optic bundle extending through the sensor probe. A light source within the sensor probe 2324 is unnecessary because the fibers can also be used to transmit light from a light source externally connected to the sensor probe. The fiber optic bundle may have a diameter that is substantially smaller when compared to the size of a CCD or CMOS chip, thereby reducing the diameter of the sensor probe 2324 and hence the diameter of the conduit 2314 and rear port 2316. This allows for a reduction of the overall size of the implantable device 2310 and the overall size of the sensor probe 2328. A smaller diameter for the sensor probe 2324 is desirable because it has to pass through the skin of the scrotum or labia to reach the rear port 2316 of the implantable device 2310 after it is implanted in the patient. Additionally, the fiber optic implementation of the sensor probe 2324 may reduce the cost of production when compared to the optical sensor implementation with CCD or CMOS chip, thereby improving affordability of making the sensor probe 2324 as a disposable device.
This application is intended to cover adaptations or variations of the present subject matter. It is to be understood that the above description is intended to be illustrative, and not restrictive. The scope of the present subject matter should be determined with reference to the appended claims, along with the full scope of legal equivalents to which such claims are entitled.
This application claims the benefit of priority under 35 § 119(e) of U.S. Provisional Patent Application Ser. No. 62/805,503, entitled “METHOD AND APPARATUS FOR MONITORING URINARY INCONTINENCE IMPLANTABLE DEVICE”, filed on Feb. 14, 2019, which is herein incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
2687131 | Raiche | Aug 1954 | A |
3138161 | Allen | Jun 1964 | A |
4019499 | Fitzgerald | Apr 1977 | A |
4428365 | Hakky | Jan 1984 | A |
4545367 | Tucci | Oct 1985 | A |
4553959 | Hickey et al. | Nov 1985 | A |
4559043 | Whitehouse et al. | Dec 1985 | A |
4592339 | Kuzmak et al. | Jun 1986 | A |
4634443 | Haber et al. | Jan 1987 | A |
4669478 | Robertson | Jun 1987 | A |
4686962 | Haber | Aug 1987 | A |
4711231 | Finegold et al. | Dec 1987 | A |
4773393 | Haber et al. | Sep 1988 | A |
4779611 | Grooters | Oct 1988 | A |
4784660 | Fischell | Nov 1988 | A |
4786276 | Haber | Nov 1988 | A |
4802479 | Haber et al. | Feb 1989 | A |
4817637 | Hillegass et al. | Apr 1989 | A |
4823800 | Compos | Apr 1989 | A |
4832680 | Haber et al. | May 1989 | A |
4846784 | Haber | Jul 1989 | A |
4857041 | Annis et al. | Aug 1989 | A |
4909785 | Burton et al. | Mar 1990 | A |
4938760 | Burton et al. | Jul 1990 | A |
4969474 | Schwarz | Nov 1990 | A |
4969892 | Burton et al. | Nov 1990 | A |
4991588 | Pflueger et al. | Feb 1991 | A |
5012822 | Schwarz | May 1991 | A |
5041077 | Kulick | Aug 1991 | A |
5041136 | Wascher et al. | Aug 1991 | A |
5047055 | Bao et al. | Sep 1991 | A |
5064434 | Haber | Nov 1991 | A |
5066303 | Bark et al. | Nov 1991 | A |
5097848 | Schwarz | Mar 1992 | A |
5112303 | Pudenz et al. | May 1992 | A |
5123428 | Schwarz | Jun 1992 | A |
5133753 | Bark et al. | Jul 1992 | A |
5149052 | Stoy et al. | Sep 1992 | A |
5154187 | Brownlee | Oct 1992 | A |
5156157 | Valenta, Jr. et al. | Oct 1992 | A |
5181921 | Makita et al. | Jan 1993 | A |
5192326 | Bao et al. | Mar 1993 | A |
5304123 | Atala et al. | Apr 1994 | A |
5308323 | Sogawa et al. | May 1994 | A |
5312430 | Rosenbluth | May 1994 | A |
5313934 | Wiita | May 1994 | A |
5320617 | Leach | Jun 1994 | A |
5334153 | McIntyre et al. | Aug 1994 | A |
5336263 | Ersek et al. | Aug 1994 | A |
5376117 | Pinchuk et al. | Dec 1994 | A |
5383896 | Gershony et al. | Jan 1995 | A |
5385561 | Cerny | Jan 1995 | A |
5411475 | Atala et al. | May 1995 | A |
5437603 | Cerny et al. | Aug 1995 | A |
5451406 | Lawin et al. | Sep 1995 | A |
5480430 | Carlisle et al. | Jan 1996 | A |
5483976 | McLaughlin et al. | Jan 1996 | A |
5496271 | Burton et al. | Mar 1996 | A |
5496370 | Hamas | Mar 1996 | A |
5499994 | Tihon et al. | Mar 1996 | A |
5518504 | Polyak | May 1996 | A |
5520700 | Beyar et al. | May 1996 | A |
5534023 | Henley | Jul 1996 | A |
5547472 | Onishi et al. | Aug 1996 | A |
5575771 | Walinsky | Nov 1996 | A |
5578009 | Kraus et al. | Nov 1996 | A |
5593443 | Carter et al. | Jan 1997 | A |
5624395 | Mikhail et al. | Apr 1997 | A |
5634877 | Salama | Jun 1997 | A |
5637074 | Andino et al. | Jun 1997 | A |
5647836 | Blake, III et al. | Jul 1997 | A |
5687714 | Kolobow et al. | Nov 1997 | A |
5749826 | Faulkner | May 1998 | A |
5803901 | Chin | Sep 1998 | A |
5830228 | Knapp et al. | Nov 1998 | A |
5938669 | Klaiber et al. | Aug 1999 | A |
5964806 | Cook et al. | Oct 1999 | A |
5976186 | Bao et al. | Nov 1999 | A |
6005020 | Loomis | Dec 1999 | A |
6013023 | Klingenstein | Jan 2000 | A |
6021781 | Thompson et al. | Feb 2000 | A |
6033413 | Mikus et al. | Mar 2000 | A |
6039686 | Kovac | Mar 2000 | A |
6042536 | Tihon et al. | Mar 2000 | A |
6045498 | Burton et al. | Apr 2000 | A |
6050937 | Benderev | Apr 2000 | A |
6053935 | Brenneman et al. | Apr 2000 | A |
6063093 | Winston | May 2000 | A |
6095969 | Karram et al. | Aug 2000 | A |
6099547 | Gellman et al. | Aug 2000 | A |
6110101 | Tihon et al. | Aug 2000 | A |
6110191 | Dehdashtian et al. | Aug 2000 | A |
6117067 | Gil-Vernet | Sep 2000 | A |
6120539 | Eldridge et al. | Sep 2000 | A |
6132465 | Ray et al. | Oct 2000 | A |
6167886 | Engel et al. | Jan 2001 | B1 |
6171231 | Connolly | Jan 2001 | B1 |
6221005 | Bruckner et al. | Apr 2001 | B1 |
6354991 | Gross et al. | Mar 2002 | B1 |
6387043 | Yoon | May 2002 | B1 |
6419624 | Burton et al. | Jul 2002 | B1 |
6419701 | Cook et al. | Jul 2002 | B1 |
6423080 | Gellman et al. | Jul 2002 | B1 |
6579224 | Burton | Jun 2003 | B1 |
6645138 | Cook et al. | Nov 2003 | B2 |
6752814 | Gellman et al. | Jun 2004 | B2 |
6786861 | Pretorius | Sep 2004 | B1 |
6970091 | Roe | Nov 2005 | B2 |
7014606 | Burton et al. | Mar 2006 | B2 |
7322360 | Fogarty et al. | Jan 2008 | B2 |
7364540 | Burton et al. | Apr 2008 | B1 |
7395822 | Burton et al. | Jul 2008 | B1 |
7481762 | Burton et al. | Jan 2009 | B2 |
7647113 | Wiribisky et al. | Jan 2010 | B2 |
7744913 | Noyes | Jun 2010 | B2 |
7771346 | Burton et al. | Aug 2010 | B2 |
7828716 | Burton et al. | Nov 2010 | B2 |
7837670 | Barath | Nov 2010 | B2 |
7914437 | Gozzi et al. | Mar 2011 | B2 |
8926494 | Cook et al. | Jan 2015 | B1 |
20020010502 | Trachtenberg | Jan 2002 | A1 |
20020055748 | Gellman et al. | May 2002 | A1 |
20020156342 | Burton et al. | Oct 2002 | A1 |
20020185138 | Single et al. | Dec 2002 | A1 |
20030208222 | Zadno-Azizi | Nov 2003 | A1 |
20040015045 | Burton et al. | Jan 2004 | A1 |
20040230206 | Gellman et al. | Nov 2004 | A1 |
20040230207 | Gillman et al. | Nov 2004 | A1 |
20050027161 | Cook et al. | Feb 2005 | A1 |
20050228225 | Hauschild et al. | Oct 2005 | A1 |
20050256364 | Burton et al. | Nov 2005 | A1 |
20060025798 | Cook et al. | Feb 2006 | A1 |
20060241339 | Cook et al. | Oct 2006 | A1 |
20060281964 | Burton et al. | Dec 2006 | A1 |
20070197954 | Keenan | Aug 2007 | A1 |
20070276342 | Lin et al. | Nov 2007 | A1 |
20080156334 | Burton et al. | Jul 2008 | A1 |
20080167518 | Burton et al. | Jul 2008 | A1 |
20100261951 | Cook et al. | Oct 2010 | A1 |
20100292530 | Cook et al. | Nov 2010 | A1 |
20110124957 | Burton et al. | May 2011 | A1 |
20120029269 | Burton et al. | Feb 2012 | A1 |
20130237763 | Qiu | Sep 2013 | A1 |
20150173708 | Cook et al. | Jun 2015 | A1 |
20210251736 | Cook et al. | Aug 2021 | A1 |
20210251737 | Cook et al. | Aug 2021 | A1 |
Number | Date | Country |
---|---|---|
2022709 | Feb 1991 | CA |
0078498 | Jun 1983 | EP |
0504934 | Sep 1992 | EP |
0639355 | Feb 1995 | EP |
0784987 | Jul 1997 | EP |
0941712 | Sep 1999 | EP |
1354568 | Oct 2003 | EP |
WO-9100069 | Jan 1991 | WO |
WO-1991000069 | Jan 1991 | WO |
WO-9601597 | Jan 1996 | WO |
WO-9820812 | May 1998 | WO |
WO-9835632 | Aug 1998 | WO |
WO-9856311 | Dec 1998 | WO |
WO-0018319 | Apr 2000 | WO |
WO-0066030 | Nov 2000 | WO |
WO-0126581 | Apr 2001 | WO |
WO-2005082276 | Sep 2005 | WO |
WO-2006091786 | Aug 2006 | WO |
2014140283 | Sep 2014 | WO |
2020168184 | Nov 2020 | WO |
Entry |
---|
“International Application Serial No. PCT US2020 018279, International Search Report dated May 25, 2020”, 5 pages. |
“International Application Serial No. PCT US2020 018279, Written Opinion dated May 25, 2020”, 6 pages. |
“U.S. Appl. No. 17/302,529, Preliminary Amendment filed 2014”, 7 pages. |
“U.S. Appl. No. 17/302,531, Preliminary Amendment filed Jun. 16, 2021”, 7 pages. |
“International Application Serial No. PCT US2020 018279, International Preliminary Report on Patentability dated Aug. 26, 2021”, 8 pgs. |
U.S. Appl. No. 10/673,028, Burton, J, et al. |
“U.S. Appl. No. 08/873,444, Final Office Action dated Sep. 27, 1999”, 6 pgs. |
“U.S. Appl. No. 08/873,444, Examiner Interview Summary dated Apr. 27, 1998”, 2 pgs. |
“U.S. Appl. No. 08/873,444, Final Office Action dated Aug. 5, 1998”, 9 pgs. |
“U.S. Appl. No. 08/873,444, Non-Final Office Action dated Jan. 13, 1998”, 7 pgs. |
“U.S. Appl. No. 08/873,444, Non-Final Office Action dated Feb. 4, 1999”, 7 pgs. |
“U.S. Appl. No. 08/873,444, Notice of Allowance dated Feb. 22, 1999”, 2 pgs. |
“U.S. Appl. No. 08/873,444, Response filed May 13, 1998 to Non-Final Office Action dated Jan. 13, 1998”, 16 pgs. |
“U.S. Appl. No. 08/873,444, Response filed Jul. 6, 1999 to Non-Final Office Action dated Feb. 4, 1999”, 6 pgs. |
“U.S. Appl. No. 08/873,444, Response filed Nov. 1, 1999 to Final Office Action dated Sep. 27, 1999”, 2 pgs. |
“U.S. Appl. No. 08/873,444, Response filed Nov. 5, 1998 to Final Office Action dated Aug. 5, 1998”, 12 pgs. |
“U.S. Appl. No. 08/873,444, Response filed Dec. 3, 1998 to Final Office Action dated Aug. 5, 1998”, 9 pgs. |
“U.S. Appl. No. 08/928,946, Non Final Office Action dated Jan. 13, 1999”, 2 pgs. |
“U.S. Appl. No. 08/928,946, Notice of Allowance dated May 3, 1999”, 6 pgs. |
“U.S. Appl. No. 08/928,946, Preliminary Amendment filed May 28, 1998”, 6 pgs. |
“U.S. Appl. No. 08/928,946, Response filed Feb. 16, 1999 to Non Final Office Action dated Jan. 13, 1999”, 2 pgs. |
“U.S. Appl. No. 08/928,946, Response filed Oct. 28, 2008 to Restriction Requirement dated Sep. 28, 2008”, 3 pgs. |
“U.S. Appl. No. 08/928,946, Restriction Requirement dated Sep. 28, 1998”, 5 pgs. |
“U.S. Appl. No. 09/345,884, Non-Final Office Action dated Mar. 19, 2001”, 7 pgs. |
“U.S. Appl. No. 09/345,884, Non-Final Office Action dated Sep. 29, 2000”, 6 pgs. |
“U.S. Appl. No. 09/345,884, Notice of Allowance dated Feb. 11, 2002”, 5 pgs. |
“U.S. Appl. No. 09/345,884, Notice of Allowance dated Sep. 24, 2001”, 2 pgs. |
“U.S. Appl. No. 09/345,884, Preliminary Amendment filed Apr. 12, 2000”, 4 pgs. |
“U.S. Appl. No. 09/345,884, Response filed Jul. 13, 2001 to Non-Final Office Action dated Mar. 19, 2001”, 8 pgs. |
“U.S. Appl. No. 09/345,884, Response filed Dec. 28, 2000 to Non-Final Office Action dated Sep. 28, 2000”, 7 pgs. |
“U.S. Appl. No. 09/415,801, Examiner Interview Summary dated May 22, 2002”, 3 pgs. |
“U.S. Appl. No. 09/415,801, Non-Final Office Action dated Mar. 27, 2001”, 4 pgs. |
“U.S. Appl. No. 09/415,801, Notice of Allowance dated Feb. 11, 2002”, 6 pgs. |
“U.S. Appl. No. 09/415,801, Notice of Allowance dated Oct. 9, 2001”, 3 pgs. |
“U.S. Appl. No. 09/415,801, Response filed Jul. 26, 2001 to Non-Final Office Action dated Mar. 27, 2001”, 16 pgs. |
“U.S. Appl. No. 09/416,193, Non-Final Office Action dated Mar. 27, 2001”, 4 pgs. |
“U.S. Appl. No. 09/416,193, Non-Final Office Action dated Jul. 15, 2002”, 5 pgs. |
“U.S. Appl. No. 09/416,193, Non-Final Office Action dated Oct. 10, 2001”, 6 pgs. |
“U.S. Appl. No. 09/416,193, Notice of Allowance dated Jan. 27, 2003”, 5 pgs. |
“U.S. Appl. No. 09/416,193, Response filed Apr. 9, 2002 to Non-Final Office Action dated Oct. 10, 2001”, 15 pgs. |
“U.S. Appl. No. 09/416,193, Response filed Jun. 26, 2001 to Non-Final Office Action dated Mar. 27, 2001”, 14 pgs. |
“U.S. Appl. No. 09/416,193, Response filed Nov. 15, 2002 to Non-Final Office Action dated Jul. 15, 2002”, 5 pgs. |
“U.S. Appl. No. 09/477,977, Advisory Action dated Aug. 21, 2002”, 5 pgs. |
“U.S. Appl. No. 09/477,977, Appeal Brief filed Feb. 10, 2003”, 21 pgs. |
“U.S. Appl. No. 09/477,977, Appeal Decision mailed Mar. 3, 2005”, 10 pgs. |
“U.S. Appl. No. 09/477,977, Examiner's Answer to Appeal Brief mailed May 7, 2003”, 6 pgs. |
“U.S. Appl. No. 09/477,977, Final Office Action dated Apr. 5, 2002”, 8 pgs. |
“U.S. Appl. No. 09/477,977, Final Office Action dated Jul. 15, 2005”, 6 pgs. |
“U.S. Appl. No. 09/477,977, Non-Final Office Action dated Feb. 27, 2007”, 5 pgs. |
“U.S. Appl. No. 09/477,977, Non-Final Office Action dated Apr. 7, 2006”, 6 pgs. |
“U.S. Appl. No. 09/477,977, Non-Final Office Action dated Aug. 2, 2001”, 8 pgs. |
“U.S. Appl. No. 09/477,977, Notice of Allowance dated Aug. 16, 2007”, 4 pgs. |
“U.S. Appl. No. 09/477,977, Notice of Allowance dated Sep. 22, 2006”, 8 pgs. |
“U.S. Appl. No. 09/477,977, Notice of Allowance dated Nov. 30, 2007”, 2 pgs. |
“U.S. Appl. No. 09/477,977, Preliminary Amendment filed Jan. 5, 2000”, 1 pg. |
“U.S. Appl. No. 09/477,977, PTO Response to Reply Brief dated Jul. 22, 2003”, 2 pgs. |
“U.S. Appl. No. 09/477,977, Reply Brief filed Jul. 7, 2003”, 2 pgs. |
“U.S. Appl. No. 09/477,977, Response filed Jul. 7, 2006 to Non-Final Office Action filed Apr. 7, 2006”, 10 pgs. |
“U.S. Appl. No. 09/477,977, Response filed Jan. 2, 2002 to Non-Final Office Action dated Aug. 2, 2001”, 5 pgs. |
“U.S. Appl. No. 09/477,977, Response filed Jan. 16, 2006 to Final Office Action dated Jul. 15, 2005”, 11 pgs. |
“U.S. Appl. No. 09/477,977, Response filed Jul. 27, 2007 to Non-Final Office Action dated Feb. 27, 2007”, 13 pgs. |
“U.S. Appl. No. 09/477,977, Response filed Aug. 5, 2002 to Final Office Action filed Apr. 5, 2002”, 20 pgs. |
“U.S. Appl. No. 09/477,977, Supplemental Preliminary Amendment filed Apr. 26, 2000”, 9 pgs. |
“U.S. Appl. No. 09/561,551,312 Amendment filed Feb. 27, 2008”, 5 pgs. |
“U.S. Appl. No. 09/561,551, Final Office Action dated Oct. 5, 2004”, 5 pgs. |
“U.S. Appl. No. 09/561,551, Final Office Action dated Oct. 31, 2006”, 8 pgs. |
“U.S. Appl. No. 09/561,551, Non-Final Office Action dated Feb. 22, 2006”, 5 pgs. |
“U.S. Appl. No. 09/561,551, Non-Final Office Action dated Apr. 5, 2005”, 5 pgs. |
“U.S. Appl. No. 09/561,551, Non-Final Office Action dated Apr. 17, 2007”, 4 pgs. |
“U.S. Appl. No. 09/561,551, Non-Final Office Action dated Jul. 9, 2001”, 9 pgs. |
“U.S. Appl. No. 09/561,551, Non-Final Office Action dated Dec. 18, 2003”, 4 pgs. |
“U.S. Appl. No. 09/561,551, Notice of Allowance dated Nov. 28, 2007”, 2 pgs. |
“U.S. Appl. No. 09/561,551, PTO Response to 312 Amendment dated Apr. 21, 2008”, 2 pgs. |
“U.S. Appl. No. 09/561,551, Response filed Jan. 5, 2005 to Final Office Action filed Oct. 5, 2004”, 9 pgs. |
“U.S. Appl. No. 09/561,551, Response filed Apr. 2, 2007 to Final Office Action filed Oct. 31, 2006”, 10 pgs. |
“U.S. Appl. No. 09/561,551, Response filed Jun. 17, 2004 to Non-Final Office Action filed Dec. 18, 2003”, 8 pgs. |
“U.S. Appl. No. 09/561,551, Response filed Aug. 22, 2006 to Non-Final Office Action filed Feb. 22, 2006”, 11 pgs. |
“U.S. Appl. No. 09/561,551, Response filed Sep. 6, 2005 to Non-Final Office Action filed Apr. 5, 2005”, 8 pgs. |
“U.S. Appl. No. 09/561,551, Response filed Sep. 17, 2007 to Non-Final Office Action filed Apr. 17, 2007”, 8 pgs. |
“U.S. Appl. No. 09/561,551, Response filed Nov. 9, 2001 to Non-Final Office Action filed Jul. 9, 2001”, 20 pgs. |
“U.S. Appl. No. 10/167,563, Final Office Action dated May 4, 2005”, 6 pgs. |
“U.S. Appl. No. 10/167,563, Non-Final Office Action dated Sep. 23, 2004”, 5 pgs. |
“U.S. Appl. No. 10/167,563, Notice of Allowance dated Oct. 4, 2005”, 4 pgs. |
“U.S. Appl. No. 10/167,563, Preliminary Amendment filed Jun. 11, 2002”, 3 pgs. |
“U.S. Appl. No. 10/167,563, Response filed Jan. 24, 2005 to Non-Final Office Action dated Sep. 23, 2004”, 12 pgs. |
“U.S. Appl. No. 10/167,563, Response filed Sep. 6, 2005 to Final Office Action dated May 4, 2005”, 11 pgs. |
“U.S. Appl. No. 10/167,565, Non-Final Office Action dated Feb. 11, 2003”, 6 pgs. |
“U.S. Appl. No. 10/167,565, Notice of Allowance dated May 30, 2003”, 5 pgs. |
“U.S. Appl. No. 10/167,565, Preliminary Amendment filed Jun. 11, 2002”, 2 pgs. |
“U.S. Appl. No. 10/167,565, Response filed May 9, 2003 to Non-Final Office Action dated Feb. 11, 2003”, 7 pgs. |
“U.S. Appl. No. 10/429,924, Final Office Action dated Dec. 13, 2006”, 7 pgs. |
“U.S. Appl. No. 10/429,924, Non-Final Office Action dated Mar. 17, 2008”, 8 pgs. |
“U.S. Appl. No. 10/429,924, Non-Final Office Action dated Mar. 23, 2006”, 8 pgs. |
“U.S. Appl. No. 10/429,924, Non-Final Office Action dated Jul. 5, 2007”, 7 pgs. |
“U.S. Appl. No. 10/429,924, Notice of Allowance dated Sep. 16, 2008”, 4 pgs. |
“U.S. Appl. No. 10/429,924, Preliminary Amendment filed May 5, 2003”, 3 pgs. |
“U.S. Appl. No. 10/429,924, Response filed Jun. 13, 2007 to Final Office Action dated Dec. 13, 2006”, 8 pgs. |
“U.S. Appl. No. 10/429,924, Response filed Aug. 5, 2008 to Non-Final Office Action dated Mar. 17, 2008”, 10 pgs. |
“U.S. Appl. No. 10/429,924, Response filed Sep. 22, 2006 to Non-Final Office Action dated Mar. 23, 2006”, 10 pgs. |
“U.S. Appl. No. 10/429,924, Response filed Dec. 5, 2007 to Non-Final Office Action dated Jul. 5, 2007”, 10 pgs. |
“U.S. Appl. No. 10/673,028, Non-Final Office Action dated Jun. 2, 2004”, 4 pgs. |
“U.S. Appl. No. 10/673,028, Preliminary Amendment filed Sep. 26, 2003”, 3 pgs. |
“U.S. Appl. No. 10/932,414, Advisory Action dated Aug. 12, 2008”, 3 pgs. |
“U.S. Appl. No. 10/932,414, Appeal Brief filed Oct. 21, 2008”, 26 pgs. |
“U.S. Appl. No. 10/932,414, Examiner's Answer to Appeal Brief dated Mar. 2, 2009”, 9 pgs. |
“U.S. Appl. No. 10/932,414, Final Office Action dated Mar. 21, 2008”, 7 pgs. |
“U.S. Appl. No. 10/932,414, Final Office Action dated Jun. 15, 2007”, 7 pgs. |
“U.S. Appl. No. 10/932,414, Non-Final Office Action dated Feb. 12, 2007”, 6 pgs. |
“U.S. Appl. No. 10/932,414, Non-Final Office Action dated Apr. 17, 2006”, 5 pgs. |
“U.S. Appl. No. 10/932,414, Non-Final Office Action dated Sep. 14, 2007”, 7 pgs. |
“U.S. Appl. No. 10/932,414, Notice of Allowance dated Jan. 6, 2011”, 4 pgs. |
“U.S. Appl. No. 10/932,414, Notice of Allowance dated Oct. 23, 2006”, 4 pgs. |
“U.S. Appl. No. 10/932,414, Preliminary Amendment filed Sep. 2, 2004”, 5 pgs. |
“U.S. Appl. No. 10/932,414, Preliminary Amendment filed Dec. 14, 2004”, 3 pgs. |
“U.S. Appl. No. 10/932,414, PTO Response to 312 Amendment dated Apr. 19, 2011”, 2 pgs. |
“U.S. Appl. No. 10/932,414, Reply Brief filed May 4, 2009”, 4 pgs. |
“U.S. Appl. No. 10/932,414, Response filed May 14, 2007 to Non-Final Office Action dated Feb. 12, 2007”, 8 pgs. |
“U.S. Appl. No. 10/932,414, Response filed Jul. 7, 2006 to Non-Final Office Action dated Apr. 17, 2006”, 7 pgs. |
“U.S. Appl. No. 10/932,414, Response filed Jul. 18, 2008 to Final Office Action dated Mar. 21, 2008”, 7 pgs. |
“U.S. Appl. No. 10/932,414, Response filed Aug. 15, 2007 to Final Office Action dated Jun. 15, 2007”, 7 pgs. |
“U.S. Appl. No. 10/932,414, Response filed Dec. 14, 2007 to Non-Final Office Action dated Sep. 14, 2007”, 8 pgs. |
“U.S. Appl. No. 10/932,414, Supplemental Notice of Allowability dated Nov. 27, 2006”, 2 pgs. |
“U.S. Appl. No. 11/063, 229, Advisory Action dated Nov. 13, 2009”, 3 pgs. |
“U.S. Appl. No. 11/063,229, Advisory Action dated Oct. 31, 2008”, 3 pgs. |
“U.S. Appl. No. 11/063,229, Examiner Interview Summary dated Apr. 9, 2008”, 5 pgs. |
“U.S. Appl. No. 11/063,229, Final Office Action dated Jul. 22, 2008”, 11 pgs. |
“U.S. Appl. No. 11/063,229, Final Office Action dated Sep. 2, 2009”, 18 pgs. |
“U.S. Appl. No. 11/063,229, Non Final Office Action dated Jun. 12, 2007”, 10 pgs. |
“U.S. Appl. No. 11/063,229, Non-Final Office Action dated Jan. 8, 2008”, 10 pgs. |
“U.S. Appl. No. 11/063,229, Non-Final Office Action dated Mar. 6, 2009”, 12 pgs. |
“U.S. Appl. No. 11/063,229, Non-Final Office Action dated Dec. 28, 2009”, 12 pgs. |
“U.S. Appl. No. 11/063,229, Response filed Apr. 8, 2008 to Non-Final Office Action filed Jan. 8, 2008”, 8 pgs. |
“U.S. Appl. No. 11/063,229, Response filed Jun. 8, 2009 to Non Final Office Action dated Mar. 6, 2009”, 6 pgs. |
“U.S. Appl. No. 11/063,229, Response filed Oct. 12, 2007 to Non-Final Office Action dated Jun. 12, 2007”, 8 pgs. |
“U.S. Appl. No. 11/063,229, Response filed Oct. 22, 2008 to Final Office Action dated Jul. 22, 2008”, 8 pgs. |
“U.S. Appl. No. 11/063,229, Response filed Nov. 2, 2009 to Final Office Action dated Sep. 2, 2009”, 6 pgs. |
“U.S. Appl. No. 11/120,631, Non-Final Office Action dated Aug. 24, 2006”, 6 pgs. |
“U.S. Appl. No. 11/120,631, Preliminary Amendment filed May 3, 2005”, 1 pg. |
“U.S. Appl. No. 11/331,838, Non-Final Office Action dated Jul. 22, 2009”, 5 pgs. |
“U.S. Appl. No. 11/331,838, Notice of Allowance dated Mar. 29, 2010”, 9 pgs. |
“U.S. Appl. No. 11/331,838, Preliminary Amendment filed Aug. 29, 2006”, 6 pgs. |
“U.S. Appl. No. 11/331,838, Response filed Dec. 22, 2009 to Non Final Office Action dated Jul. 22, 2009”, 9 pgs. |
“U.S. Appl. No. 11/361,016, Examiner Interview Summary dated Jan. 13, 2010”, 4 pgs. |
“U.S. Appl. No. 11/361,016, Final Office Action dated Sep. 4, 2009”, 20 pgs. |
“U.S. Appl. No. 11/361,016, Non-Final Office Action dated Jan. 21, 2009”, 17 pgs. |
“U.S. Appl. No. 11/361,016, Response filed May 21, 2009 to Non Final Office Action dated Jan. 21, 2009”, 16 pgs. |
“U.S. Appl. No. 11/622,384, Preliminary Amendment filed Jan. 11, 2007”, 3 pgs. |
“U.S. Appl. No. 12/051,515, Non-Final Office Action dated Mar. 24, 2010”, 13 pgs. |
“U.S. Appl. No. 12/051,515, Non-Final Office Action dated Oct. 9, 2009”, 6 pgs. |
“U.S. Appl. No. 12/051,515, Notice of Allowance dated Jul. 2, 2010”, 5 pgs. |
“U.S. Appl. No. 12/051,515, Response filed Feb. 5, 2010 to Non Final Office Action dated Oct. 9, 2009”, 10 pgs. |
“U.S. Appl. No. 12/051,515, Response filed May 7, 2010 to Non Final Office Action dated Mar. 24, 2010”, 8 pgs. |
“U.S. Appl. No. 12/054,662, Non-Final Office Action dated Jul. 9, 2009”, 14 pgs. |
“U.S. Appl. No. 12/411,806 , Response filed Apr. 5, 2012 to Non Final Office Action dated Oct. 6, 2011”, 10 pgs. |
“U.S. Appl. No. 12/411,806, Final Office Action dated Apr. 26, 2012”, 17 pgs. |
“U.S. Appl. No. 12/411,806, Final Office Action dated Aug. 16, 2013”, 20 pgs. |
“U.S. Appl. No. 12/411,806, Non Final Office Action dated Jan. 2, 2013”, 18 pgs. |
“U.S. Appl. No. 12/411,806, Non Final Office Action dated Apr. 10, 2014”, 24 pgs. |
“U.S. Appl. No. 12/411,806, Non Final Office Action dated Oct. 6, 2011”, 17 pgs. |
“U.S. Appl. No. 12/411,806, Notice of Allowance dated Sep. 2, 2014”, 10 pgs. |
“U.S. Appl. No. 12/411,806, Response filed Feb. 14, 2014 to Final Office Action dated Aug. 16, 2013”, 13 pgs. |
“U.S. Appl. No. 12/411,806, Response filed Jul. 2, 2013 to Non Final Office Action dated Jan. 2, 2013”, 11 pgs. |
“U.S. Appl. No. 12/411,806, Response filed Oct. 26, 2012 to Final Office Action dated Apr. 26, 2012”, 11 pgs. |
“U.S. Appl. No. 12/700,235 , Response filed Apr. 9, 2013 to Non Final Office Action dated Oct. 9, 2012”, 10 pgs. |
“U.S. Appl. No. 12/700,235, Examiner Interview Summary dated Dec. 6, 2013”, 3 pgs. |
“U.S. Appl. No. 12/700,235, Final Office Action dated Aug. 1, 2013”, 17 pgs. |
“U.S. Appl. No. 12/700,235, Non Final Office Action dated Oct. 9, 2012”, 14 pgs. |
“U.S. Appl. No. 12/838,927, Non Final Office Action dated Sep. 7, 2011”, 4 pgs. |
“U.S. Appl. No. 13/080,350, Non Final Office Action dated Aug. 15, 2013”, 7 pgs. |
“U.S. Appl. No. 14/589,361, Non Final Office Action dated Oct. 7, 2015”, 10 pgs. |
“U.S. Appl. No. 14/589,361, Preliminary Amdnedment filed Apr. 24, 2015”, 5 pgs. |
“Australian Application Serial No. 200521611 Examiner's report dated Dec. 8, 2009”, 4 pgs. |
“Canadian Application Serial No. 2,387,963, Office Action dated Feb. 20, 2007”, 2 pgs. |
“Canadian Application Serial No. 2,387,963, Office Action dated Nov. 14, 2007”, 2 pgs. |
“European Application Serial No. 05713846.3, Office Action dated Aug. 7, 2009”, 4 pgs. |
“European Application Serial No. 08075007.8, Extended European Search Report dated Oct. 30, 2009”, 6 pgs. |
“European Application Serial No. 08075007.8, Office Action dated Jul. 5, 2010”, 1. |
“International Application No. PCT/US2005/005370, International Preliminary Report on Patentability dated Sep. 8, 2006”, 8 pgs. |
“International Application No. PCT/US2005/005370, International Search Report and Written Opinion dated Jun. 9, 2005”, 13 pgs. |
“International Application No. PCT/US98/12368, International Preliminary Examination Report dated Sep. 20, 1999”, 6 pgs. |
“International Application No. PCT/US98/12368, Written Opinion dated Mar. 19, 1999”, 6 pgs. |
“International Application Serial No. PCT/US2006/006546, International Search Report and Written Opinion dated Jun. 7, 2006”, 12 pgs. |
Gregori, Andrea, et al., “Implantation of an Adjustable Continence Therapy System Using Local Anesthesia in Patients With Post-Radical Prostatectomy”, (May 1, 2008), 5 Pgs. |
Gregori, Andrea, et al., “Transrectal Ultrasound Guided Implantation of the Proact Adjustable Continence Therapy System in Patients With Post-Radical Prostatectomy Stress Urinary Incontinence: a Pilot Study”, The Journal of Urology, (Nov. 1, 2006), 5 pgs. |
Gregori, Andrea, et al., “Transrectal Ultrasound-Guided Implantation of Adjustable Continence Therapy (Proact): Surgical Technique and Clinical Results After a Mean Follow-Up of 2 Years”, (Nov. 30, 2009), 7 pgs. |
Lima, S.V.C., “Further Experience with the Periurethral Expander: A New Type of Artificial Sphincter”, British Journal of Urology (1997), 460-462. |
Lima, Salvador C., et al., “Combined Use of Enterocystoplasty and a new Type of Artificial Sphincter in the Treatment of Urinary Incontinence”, The Journal of Urology, 156(2 Pt 2), (Applicant notes that the attached cover sheet states “Papers Presented at Annual Meeting of the Section on Urology, American Academy of Pediatrics”, San Francisco, CA Oct. 14-16, 1995), (Aug. 1996), 622-624. |
U.S. Appl. No. 17/302,529, filed May 5, 2021, Method and Apparatus for Monitoring Implantable Device for Urinary Continence. |
U.S. Appl. No. 17/302,531, filed May 5, 2021, Method and Apparatus for Monitoring Implantable Device for Urinary Continence. |
“European Application Serial No. 20714332.2, Response Filed Mar. 23, 2022 to Communication pursuant to Rules 161(1) and 162 EPC dated Sep. 21, 2021”, 13 pgs. |
Number | Date | Country | |
---|---|---|---|
20200261200 A1 | Aug 2020 | US |
Number | Date | Country | |
---|---|---|---|
62805503 | Feb 2019 | US |